semaj83/ctmatch_classification huggingface dataset:
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 25.0-999.0,  Influenza Healthy individuals aged 25-40 years, or ≥65 years old. 2. Able to understand and give informed consent. 3. Women of child-bearing potential (not surgically sterile via tubal ligation, bilateral oophorectomy or hysterectomy or who are not postmenopausal for ≥1 year) must agree to practice adequate contraception that may but is not limited to, abstinence, monogamous relationship with vasectomized partner, barrier methods such as condoms, diaphragms, spermicides, intrauterine devices, and licensed hormonal methods for 30 days before and 30 days after trivalent Influenza vaccination  Receipt of immune products Receipt of blood products 3 months prior to study entry or expected receipt through 6 months after study entry Receipt of any live virus vaccines within 4 weeks prior to study entry or expected receipt within 4 weeks after study entry* Receipt of any inactivated vaccine within 2 weeks or expected receipt within 2 weeks after study entry* Receipt of the 2010-2011 influenza vaccine 2. Documented influenza infection during the 2010-2011 influenza season. Not excluded from the study, volunteers with prior upper respiratory infections during the 2010-2011 influenza illness. 3. Presence of co-morbidities or immunosuppressive states such as Chronic medical problems including (but not limited to) insulin dependent diabetes, severe heart disease, severe lung disease, severe liver disease, severe kidney disease, auto immune diseases, severe gastrointestinal diseases, and uncontrolled hypertension Alcohol or drug abuse and psychiatric conditions that in the opinion of the investigator would preclude compliance with the trial or interpretation of safety or endpoint data Impaired immune function or chronic infections including (but not limited to) HIV, hepatitis B or C; organ transplant; cancer; current and/or expected receipt of chemotherapy, radiation therapy or any other cytotoxic or immunosuppressive therapy [i.e. more than 10 mg of prednisone given daily or on alternative days for 2 weeks or more in the past 3 months*; receipt of high-dose inhaled steroids is also an (nasal and topical steroids are allowed.)], congenital immunodeficiency, anatomical or functional asplenia Pregnancy or breast feeding 4. Conditions that could affect the safety of the volunteers such as
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Breast Cancer Early stage breast cancer patients taking adjuvant endocrine therapy (ie, tamoxifen, anastrozole, letrozole, exemestane) Age ≥ 60 years Must have broadband internet access at home (to enable the base for the system to communicate to the Vitality server) Must have a landline or mobile phone  Non-English speaking patients
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 50.0-999.0,  Herpes Zoster Varicella-zoster Vaccine All Groups Must not have a fever of ≥100.4° F on the day of vaccination Any underlying chronic illness must be in stable condition History of varicella or residence in a VZV-endemic area for ≥30 years Group 1 years of age or older Took part in the Shingles Prevention Study (SPS) (V211-004, NCT00007501) and received a single dose of Zoster Vaccine, Live ≥10 years prior to enrollment in this study Group 2 years of age or older Group 3  All Groups History of hypersensitivity reaction to any vaccine component or an anaphylactic/anaphylactoid reaction to neomycin Prior history of herpes zoster Pregnant or breast-feeding, or expecting to conceive within the duration of the study Has been treated with immunoglobulin or any blood products, other than autologous (self-donated) blood transfusion, in the 5 months prior to vaccination Received any other vaccine within 4 weeks prevaccination On immunosuppressive therapy Has known or suspected immune dysfunction Is taking any non-topical antiviral therapy with activity against herpesviruses, including, but not limited to acyclovir, famciclovir, valacyclovir, and ganciclovir Groups 2, 3, and 4
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.5-999.0,  Egg Allergy Eligible for Vaccination Against Influenza Age > 6 months Clinical history of allergic symptoms (hives, swelling, vomiting, respiratory problems, low blood pressure) within 2 hours after ingestion of egg OR Eczema/atopic dermatitis worsened by egg exposure Confirmation of clinical history by positive egg skin prick test or serum egg-specific IgE or a positive oral food challenge. [The >95% positive predictive values of egg serum IgE in subjects >2 years old with atopic dermatitis is 6 kU/L or greater. In subjects >2 years old without atopic dermatitis, the value is 7 kU/L or greater. In subjects less than 2 years old, the value is 2 kU/L or greater.] FluMist (LAIV) cohort: Patients age 2-49 years a history of asthma symptoms or treatment within the past 12 months will receive intranasal FluMist Flu Shot (TIV) Intramuscular influenza vaccine cohort: Patients 6 months to 2 yrs or > 49 years or WITH a history of asthma symptoms / treatment within the past 12 months. History/Treatment of asthma in the past 12 months is defined as follows: 1. wheezing in the past 12 months 2. use of inhaled corticosteroids (ICS), combined ICS / long acting beta agonist (LABA), or oral steroid in the past 12 months 3. emergency room or acute care visit or hospitalization for asthma or wheezing in the past 12 months  Subjects who potentially have outgrown their egg allergy (no allergic reaction with ingestion of whole egg in the past 18 months and an egg serum specific IgE level ≤2 kU/L) Pregnancy Current moderate to severe illness with a fever Allergy to other components of the vaccine gentamicin, gelatin, arginine, thimerosal or a history of a previous allergic reaction to the influenza vaccine Abnormal Vital Signs History of Guillain-Barre' Syndrome (GBS) HIV/AIDS or another disease that affects the immune system, or cancer Long term health problems that are contraindicated for the LAIV or TIV
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Hemodialysis Patients Patients under chronic hemodialysis  history of flu infection in last month history of flu vaccination in 2009 hospitalization in last month taking immune suppressants drugs hemodialysis less than twice weekly
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 20.0-999.0,  H1N1 Influenza Virus Influenza Rapid Test Influenza A(+) B(-) Influenza Rapid Test Influenza A(+) B(+) Influenza Rapid Test Influenza A(-) B(-) was negative control  Influenza Rapid Test Influenza A(-) B(+)
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Amyotrophic Lateral Sclerosis Aged 18 to 80 years old, inclusive, on Day 1 Diagnosis of sporadic or familial ALS Onset of first ALS symptoms within 24 months prior to Day 1 World Federation of Neurology El Escorial are met for a possible, laboratory-supported probable, probable, or definite ALS diagnosis Upright slow vital capacity (SVC) of 65% or more at screening Patients taking or not taking Riluzole are eligible for this study: if a patient has never taken Riluzole, he or she is eligible; if a patient is currently taking Riluzole, he or she must have been on a stable dose for at least 60 days; if a patient has discontinued Riluzole, he or she must have stopped taking it for at least 30 days Must be able to swallow tablets at the time of study entry  Other medically significant illness Clinically significant abnormal laboratory values Pregnant women or women breastfeeding Prior exposure to dexpramipexole Currently taking pramipexole or other dopamine agonists. Other protocol-defined inclusion/
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Rheumatoid Arthritis Patients suffering from RA Aged 18 to 64 years old  Active disease requiring a change in drug regimen Known allergy to vaccine
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 60.0-999.0,  Healthy years of age or older willing to complete daily and monthly questionnaires willing to receive the fall influenza vaccination as part of the study protocol willing to provide 3 blood samples, 3 saliva samples, and 2 stool samples and answer a food frequency questionnaire over the course of the study willing to discontinue any immune-enhancing dietary supplements ( e.g., prebiotics and fiber supplements, probiotics, echinacea, fish oil, vitamin E >100% of the RDA or >15 mg/day) willing to take the study fiber for 24 weeks willing to provide a social security number to receive study payment Note: the subject can still participate if unwilling to provide SS#, but no financial reimbursement can be provided had a cold in the last 12 months able to take foods and the study fiber without the aid of another person eligible and willing to receive the influenza vaccine for the current year. That is, you cannot have already received an influenza vaccine for the 2010/2011 season prior to receiving it from the study  current smoker chronic allergies involving the upper respiratory tract (Chronic = taking allergy medicine daily) taking any medication for constipation or diarrhea currently taking any anti-inflammatory drugs on a regular basis currently treated for Alzheimer's disease allergy to milk or a serious allergy to eggs (note lactose intolerance should not be a problem because 1 fiber packet contains only 0.3 g of lactose whereas 1 cup of milk contains 12.8 g of lactose) currently being treated for any known illnesses or conditions that may impact perceived health such as HIV/AIDS, immune modulating diseases (autoimmune, hepatitis, cancer, etc.), diabetes, kidney disease, gastrointestinal diseases (gastric ulcers, Crohn's, ulcerative colitis, etc.) received chemotherapy or other immune suppressing therapy within the last year received antibiotic therapy in the past two months receiving supplemental oxygen
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Influenza Male or Female, of all ages (assuming appropriate consent is obtained). 2. Must currently be exhibiting symptoms characteristic of influenza-like-illness (ILI). For example: 1. Fever, ≥ 38º C (100º F), either at the time of the visit or onset within the past two (2) days. 2. Nasal congestion 3. Rhinorrhea 4. Sore throat 5. Cough 6. Headache 7. Myalgia 8. Malaise  Has undergone treatment with anti-influenza antivirals within the previous 7 days, including, for example, one or more of the following, but not be limited to Amantadine, Rimantadine, Ribavirin, Oseltamivir, Zanamivir or any other antiviral currently available in these classes. 2. Has been vaccinated by means of an influenza nasal spray/mist vaccine within the previous 7 days. 3. Unable to understand and consent to participation; for minors this includes parent or legal guardian
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-55.0,  Influenza Provision of signed and dated, written informed consent prior to any study-specific procedures Subjects must be able to understand and be willing to comply with study procedures, restrictions, and requirements Healthy male and non-fertile female subjects aged 18 and 55 years inclusive Female subjects must have a negative urine pregnancy test at screening must not be lactating or breastfeeding and must be of non-childbearing potential Male subjects should be willing to use barrier contraception during sexual intercourse Body weight 50 to 100 kg inclusive and body mass index (BMI) 18 to 30 kg/m2 inclusive Clinically non-significant findings on physical examination in relation to age Negative Rapid Flu Test (TRU FLU® kit) Negative nasal examination upon admission to the study center  History and/or presence of any clinically significant disease or disorder such as cardiovascular, pulmonary, renal, hepatic, neurological, gastrointestinal and psychiatric/mental disease/disorders History and/or presence of hepatic or renal disease or any other condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs. Subjects with a surgical history of the gastrointestinal tract should also be excluded from participation in the study Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of the administration of the investigational product which is symptomatic enough to affect study conduct or the well-being of the subject History and/or presence of asthma or recurrent sinusitis. Active rhinitis at screening or upon admission to the study center Any clinically significant nasal septum deviation, presence of septum perforations, and history of recurrent epistaxis and nasal polyps Subjects with a history of sinus surgery and/or persistent hypertrophic inferior turbinates History of vaccination with live vaccine within 7 days or attenuated vaccine within 14 days of the administration of the investigational product Any clinically significant abnormalities in clinical laboratory safety assessment results A positive result at screening on serum hepatitis B surface antigen, hepatitis C antibodies and HIV antibodies Significant orthostatic reaction at screening or upon admission to the study center as judged by the Principal Investigator
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Fasting Is the individual a healthy, normal adult man and women who volunteers to participate? Is s/he within 18 and 45 years of age, inclusive? Is his/her BMI between 19 and 30, inclusive? Is she willing to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra-uterine contraceptive device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been surgically sterile or post-menopausal at least six months prior to entering into the study? Is s/he considered reliable and capable of understanding his/her responsibility and role in the study? Has s/he provided written informed consent? A no answer to any of the above questions indicates that the individual is ineligible for enrollment  Does the individual have a history of allergy or hypersensitivity to desloratadine? Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Is she nursing? Does s/he have serious psychological illness? Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse? Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test? Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period?  Has s/he used any prescription drug, other than hormonal contraceptives, during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation? Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Fed Is the individual a healthy, normal adult man and women who volunteers to participate? Is s/he within 18 and 45 years of age, inclusive? Is his/her BMI between 19 and 30, inclusive? Is she willing to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra-uterine contraceptive device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been surgically sterile or post-menopausal at least six months prior to entering into the study? Is s/he considered reliable and capable of understanding his/her responsibility and role in the study? Has s/he provided written informed consent? A no answer to any of the above questions indicates that the individual is ineligible for enrollment  Does the individual have a history of allergy or hypersensitivity to desloratadine? Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety? Is she nursing? Does s/he have serious psychological illness? Does s/he have significant history (within the past year) or clinical evidence of alcohol or drug abuse? Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test? Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period?  Has s/he used any prescription drug, other than hormonal contraceptives, during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation? Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
Patient description: A 67-year-old healthy woman came to the clinic to have her flu shot in early October. She works at a rehab center and has no underlying disease. It is her first vaccination this year. she is menopausal and has 4 children. She does not some. She takes daily multivitamins and anti-hypertensive drugs. She exercises regularly for 30 minutes a day at least 5 days a week. She has no allergies to any food or drugs.

Clinical trial eligibility criteria: eligible ages (years): 65.0-999.0,  Primary Health Care Aged Clinical Information Must be greater than or equal to 65 years of age Must be patients of participating physicians  Cannot speak English Cannot hear well enough to respond to questions via the telephone or do not have a caregiver who can respond to questions on their behalf